Literature DB >> 6553515

Thymosin alpha 1 restores NK-cell activity and prevents tumor progression in mice immunosuppressed by cytostatics or X-rays.

Y Umeda, A Sakamoto, J Nakamura, H Ishitsuka, Y Yagi.   

Abstract

The effect of thymosin against tumor progression was examined in mice immunosuppressed by cytostatics or X-ray irradiation. When pretreated with cytostatic agents, such as 5-fluorouracil (5-FU) or BCNU, or by X-ray, and then inoculated with P388 or L1210 leukemias, mice died rapidly within a few days. In these systems, thymosin alpha 1 given concomitantly with the cytostatic agents or after X-irradiation prevented rapid death and extended survival, although the mice eventually died with leukemia like normal mice inoculated with cells of the same tumor. Rapid death in the 5-FU-treated mice was also prevented by adoptive transfer of spleen cells from the donor mice if these had been treated with 5-FU plus thymosin alpha 1, but not if they had received 5-FU alone. However, the restorative activity of the donor spleen cells was abrogated by treatment with anti-asialo GM1, but not by treatment with anti-Thy 1 or anti-mouse Ig serum, suggesting that the effector cells in the spleen are NK cells. In fact, thymosin alpha 1, when given concomitantly with 5-FU or after X-irradiation, maintained the NK activity of spleen, which was damaged by treatment with 5-FU or X-irradiation alone. The present study indicates that thymosin alpha 1 exerts a preventive activity against progression of leukemias at least in part through an effect on NK cells or their progenitor cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6553515     DOI: 10.1007/bf00199694

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  18 in total

1.  Thymosin immunotherapy in patients with small cell carcinoma of the lung: correlation of in vitro studies with clinical course.

Authors:  S D Lipson; P B Chretien; R Makuch; D E Kenady; M H Cohen
Journal:  Cancer       Date:  1979-03       Impact factor: 6.860

2.  Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide.

Authors:  A L Goldstein; T L Low; M McAdoo; J McClure; G B Thurman; J Rossio; C Y Lai; D Chang; S S Wang; C Harvey; A H Ramel; J Meienhofer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

3.  Contribution of host immunity to cyclophosphamide therapy of a chemically-induced murine sarcoma.

Authors:  M Moore; D E Williams
Journal:  Int J Cancer       Date:  1973-03-15       Impact factor: 7.396

4.  Suppression of natural killer (NK) cell activity of spleen cells by thymocytes.

Authors:  M P Nair; S A Schwartz; G Fernandes; R Pahwa; S Ikehara; R A Good
Journal:  Cell Immunol       Date:  1981-02       Impact factor: 4.868

5.  Low natural in vivo resistance to syngeneic leukaemias in natural killer-deficient mice.

Authors:  K Kärre; G O Klein; R Kiessling; G Klein; J C Roder
Journal:  Nature       Date:  1980-04-17       Impact factor: 49.962

6.  Effects of tumor bearing on the dynamics of host hemopoietic cells.

Authors:  P K Lala
Journal:  Cancer Treat Rep       Date:  1976-12

7.  Induction of terminal deoxynucleotidyl transferase and Lyt antigens with thymosin: identification of multiple subsets of prothymocytes in mouse bone marrow and spleen.

Authors:  I Goldschneider; A Ahmed; F J Bollum; A L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

Review 8.  Relations between immunity and malignancy.

Authors:  R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1972-04       Impact factor: 11.205

9.  A glycolipid on the surface of mouse natural killer cells.

Authors:  M Kasai; M Iwamori; Y Nagai; K Okumura; T Tada
Journal:  Eur J Immunol       Date:  1980-03       Impact factor: 5.532

10.  Protective activity of thymosin against opportunistic infections in animal models.

Authors:  H Ishitsuka; Y Umeda; J Nakamura; Y Yagi
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

View more
  10 in total

Review 1.  Thymic hormones--a clinical update.

Authors:  M B Sztein; A L Goldstein
Journal:  Springer Semin Immunopathol       Date:  1986

2.  Modulation of NK activity by thymic hormones: in vitro effects of thymostimulin.

Authors:  A M Liberati; S Cinieri; M Fizzotti; M Schippa; S Ascani; V De Angelis; M Senatore; L Palmisano
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

3.  Thymic factor-induced reduction of pulmonary metastases in mice with FSA-1 fibrosarcoma.

Authors:  V J Tomazic; C R Sacasa; A Loftus; C S Suter; G E Elias
Journal:  Clin Exp Metastasis       Date:  1988 Jan-Feb       Impact factor: 5.150

4.  A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma.

Authors:  Robert G Gish; Stuart C Gordon; David Nelson; Vinod Rustgi; Israel Rios
Journal:  Hepatol Int       Date:  2009-05-08       Impact factor: 6.047

5.  Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice.

Authors:  E Garaci; A Mastino; F Pica; C Favalli
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

6.  Modulation of natural killer activity by thymosin alpha 1 and interferon.

Authors:  C Favalli; T Jezzi; A Mastino; C Rinaldi-Garaci; C Riccardi; E Garaci
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

7.  Enhancement of natural killer cell activity in mice by treatment with a thymic factor.

Authors:  F Bistoni; M Baccarini; P Puccetti; P Marconi; E Garaci
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

8.  Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life.

Authors:  Fanwen Wang; Tingting Yu; Heng Zheng; Xingzhen Lao
Journal:  Sci Rep       Date:  2018-08-17       Impact factor: 4.379

9.  Impact of thymosin α1 as an immunomodulatory therapy on long-term survival of non-small cell lung cancer patients after R0 resection: a propensity score-matched analysis.

Authors: 
Journal:  Chin Med J (Engl)       Date:  2021-11-03       Impact factor: 6.133

10.  Virucidal and Immunostimulating Activities of Monogalactosyl Diacylglyceride from Coccomyxa sp. KJ, a Green Microalga, against Murine Norovirus and Feline Calicivirus.

Authors:  Kyoko Hayashi; Satoko Komatsu; Hitoshi Kuno; Satomi Asai; Iori Matsuura; Vyankatesh Ramlu Kudkyal; Toshio Kawahara
Journal:  Mar Drugs       Date:  2022-02-10       Impact factor: 5.118

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.